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Abstract
The 134.5 protein of herpes simplex virus 1 (HSV-1) is a virus-encoded protein phosphatase 1 (PP1) regulatory protein that contributes
to viral resistance to interferon. It functions to block the shutoff of protein synthesis mediated by the double-stranded RNA-dependent
protein kinase. This requires the carboxyl terminus of the 134.5 protein to recruit PP1, forming a high-molecular-weight complex that
dephosphorylates the  subunit of translation initiation factor eIF-2 (eIF-2). In the present study, we introduced a series of point mutations
into a region in the effector domain of the 134.5 protein, which is adjacent to the PP1-binding domain. Analysis of these mutants in
virus-infected cells shows that Ser209Ala, Ser209Asp, Ser218Ala, or Trp219Tyr substitution does not affect viral response to interferon-.
In contrast, Arg215Leu or Ser218Asp substitution rendered the virus hypersensitive to interferon-, which correlates with the inability of
these 134.5 mutants to mediate dephosphorylation of eIF-2. However, Arg215Leu or Ser218Asp substitution does not disrupt the
formation of a high-molecular-weight complex required for eIF-2 dephosphorylation or binding of the 134.5 protein to PP1. These results
suggest that concerted action of the PP1-binding domain and the effector domain of the 134.5 protein is required to confer HSV-1 interferon
resistance.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
Interferons are a family of cytokines that exert antiviral,
cell growth inhibitory, and immunoregulatory activities
(Sen, 2001; Stark et al., 1998). Once bound to their cognate
receptors on the surface of cells, interferons activate the
Janus tyrosine kinase (JAK)/signal transducer and activator
(STAT) pathways, which lead to the induction of a wide
spectrum of genes. Among them are the extensively char-
acterized genes encoding 2–5 oligoadenylate synthetase,
the Mx proteins, and the double-stranded RNA-dependent
protein kinase (PKR), which form the body’s first line of
defense against virus infection. In mammalian cells, the
interferon-induced PKR is activated upon binding to dou-
ble-stranded RNA. Once activated, PKR phosphorylates the
 subunit of translation initiation factor eIF-2 (eIF-2). This
leads to the shutoff of protein synthesis and thereby the
inhibition of viral replication (Gale and Katze, 1998).
Therefore, it is not unusual that many viruses, including
herpes simplex virus 1 (HSV-1), have evolved mechanisms
to escape the antiviral response (Gale and Katze, 1998; Sen,
2001).
HSV-1 is resistant to the cellular interferon response
(Arao et al., 1997; Cheng et al., 2001a; Mossman et al.,
2000, 2001; Oberman and Panet, 1988). In HSV-1-infected
cells, viral replication is only slightly reduced in the pres-
ence of interferon (Cheng et al., 2001a; Mossman et al.,
2000). Interestingly, induction of interferon-inducible genes
is suppressed when HSV-1 proteins are expressed (Moss-
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man et al., 2001; Nicholl et al., 2000). Notably, HSV-1
infection severely reduces the activation of interferon reg-
ulatory factor-3 (IRF-3) (Preston et al., 2001). Experiments
show that HSV-1 infection also inhibits the phosphorylation
of STAT1 (Yokota et al., 2001). Recent studies indicate that
two HSV mutants, which contain a deletion of either the
ICP0 gene or the 134.5 gene, are hypersensitive to inter-
feron (Cheng et al., 2001a; Mossman et al., 2000; Mossman
and Smiley, 2002). When provided in trans, ICP0 is able to
reverse the interferon-mediated repression of viral gene
expression (Eidson et al., 2002; Harle et al., 2002b). It
appears that expression of ICP0 inhibits the induction of
interferon-stimulated genes (Eidson et al., 2002), but the
precise role of ICP0 remains undefined. Unlike ICP0, the
cellular target of the 134.5 protein has been extensively
characterized. It is well established that the 134.5 protein
functions to prevent the PKR-mediated translation inhibi-
tion (Chou et al., 1995; Chou and Roizman, 1992, 1994; He
et al., 1997).
The 134.5 protein of HSV-1(F) consists of 263 amino
acids with a large amino-terminal domain, a linker region
containing repeats of three amino acids (AlaThrPro), and a
carboxyl-terminal domain (Chou and Roizman, 1986,
1990). Early studies indicate HSV mutants that fail to ex-
press the 134.5 protein induce translational shutoff and are
highly attenuated in animal models (Chou et al., 1990; Chou
and Roizman, 1992; Valyi-Nagy et al., 1994). These mu-
tants replicate efficiently in PKR or interferon receptor
knockout mice, but not in wild-type mice (Chou et al., 1990;
Leib et al., 1999, 2000). We have recently demonstrated that
the functional interaction between the 134.5 protein and
cellular protein phosphatase 1 (PP1) contributes to HSV-1
resistance to interferon, which requires the involvement of
the carboxyl-terminal domain of the 134.5 protein (Cheng
et al., 2001a). In HSV-1-infected cells, the carboxyl termi-
nus of the 134.5 protein recruits PP1, forming a high-
molecular-weight complex that specifically dephosphory-
lates the  subunit of translation initiation factor eIF-2 (He
et al., 1998). Earlier deletion studies suggest that the car-
boxyl-terminal domain of the 134.5 protein contains a
PP1-binding domain and an effector domain (Cheng et al.,
2001b; He et al., 1996, 1998). The PP1-binding domain
contains 12 amino acids with a signature sequence motif of
(Arg/Lys)(Val/Ile)XaaPhe found in many PP1-binding pro-
teins (Cohen, 2002; Egloff et al., 1997). Interestingly,
amino acid substitutions in this motif render HSV-1 sensi-
tive to interferon-/ (Cheng et al., 2001a). The effector
domain consists of 59 amino acids, and its precise role is not
yet understood. However, previous studies showed that an
HSV mutant that contains a deletion of the effector domain
is hypersensitive to interferon-/ (Cheng et al., 2001a).
The present study was undertaken to evaluate the role of
the effector domain of the 134.5 protein in interferon
resistance. We have focused on a region in the effector
domain that is in close proximity to the PP1 domain. We
show that point mutations in the 134.5 protein have dif-
ferential effects on HSV-1 resistance to interferon. We fur-
ther demonstrate that HSV-1 resistance to interferon corre-
lates well with the ability of the 134.5 protein to mediate
eIF-2 dephosphorylation, a complex process that involves
not only the PP1-binding domain, but also the effector
domain.
Results
Construction of recombinant viruses with mutations in the
effector domain of the 134.5 protein
To study the function of the effector domain, we intro-
duced a series of point mutations into the 134.5 protein. As
illustrated in Fig. 1, the carboxyl terminus of the 134.5
protein contains a PP1-binding domain and an effector do-
main. We have focused on a region in the effector domain
that is in close proximity to the PP1-binding motif. Muta-
tions were performed at serine 209, arginine 215, serine
218, and tryptophan 219, which are conserved in the 134.5
protein of HSV-1 and HSV-2. We mutated arginine 215 to
leucine, tryptophan 219 to tyrosine, serine 209 to alanine,
and serine 218 to alanine. In addition, we mutated the serine
209 and serine 218 to aspartic acid, respectively. These
mutants were then recombined into the genome of HSV-1
for examining the effects of charge, polarity, or size of
amino acids used for substitutions.
We constructed recombinant viruses by using the HSV-
BAC (bacterial artificial chromosome) system (Horsburgh
et al., 1999). To facilitate our experiments, we initially
constructed recombinant virus KY0081, which lacks 144 bp
in the carboxyl terminus of the 134.5 gene. An RR1 strain
of Escherichia coli containing a wild-type HSV-BAC DNA
was transformed with a plasmid containing an HSV-1(F)
BamHI S fragment with a 144-bp deletion in the 134.5
gene, resulting in the recombinant KY0081. The mutant
KY0081 was then used as a backbone to construct recom-
binant viruses with amino acid substitutions. RR1 cells
harboring the deletion mutant KY0081 were subsequently
transformed with various mutant plasmids and selected by
antibiotic and temperature selection as described under Ma-
terials and methods. Vero cells were then transfected with
the recombinant viral DNA to obtain the desired viruses.
To verify the virus constructs, Southern blot analysis was
carried out after the NotI digestion of viral DNA (He et al.,
1996). As seen in Fig. 2A, parental HSV-BAC, HSV-1(F),
MC0113, MC0020, MC0115, MC0114, and MC0021
yielded an 822-bp fragment. KY0081, which has a 144-bp
deletion in the carboxyl terminus of the 134.5 gene,
yielded a 678-bp fragment. MC0112 yielded two bands at
494 and 328 bp because of an introduction of an additional
NotI site in the 134.5 gene. To detect expression of the
134.5 protein, Western blot analysis was performed. Fig.
2B shows that comparable levels of the 134.5 protein were
expressed for recombinant viruses to that of wild-type HSV-
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1(F) with anti-134.5 antibody (Cheng et al., 2002). Expres-
sion of the 134.5 gene in KY0081 was not detected by the
anti-134.5 antibody due to the 144-bp deletion in the car-
boxyl terminus of 134.5. Taken together, these experi-
ments indicate that the recombinant viruses constructed
contain the expected 134.5 gene derivatives.
The effect of amino acid substitutions in the 134.5
protein on HSV-1 response to interferon-
We analyzed the effects of mutations on viral response to
interferon-. This was done by measuring the replication of
wild-type virus and the mutant viruses in Vero cells un-
treated or pretreated with interferon- (1000 U/ml) for 20 h.
At 72 h after virus infection, cells were harvested, and virus
yields were measured by plaque assays. The data summa-
rized in Table 1 show that in the absence of interferon,
wild-type HSV-1(F) reached a virus titer of 3.5  108
PFU/ml, and R3616 reached a titer of 1.1  107 PFU/ml.
There is an approximately 30-fold decrease in virus titer for
R3616 compared to HSV-1(F), which is attributed to the
deletion of the 134.5 gene. Replication of MC0112
(Ser209Ala substitution), MC0113 (Ser209Asp substitu-
tion), MC0115 (Ser218Ala substitution), and MC0021
(Trp219Tyr substitution) is similar to that of HSV-1(F).
However, replication of MC0020 (Arg215Leu substitution)
and MC0114 (Ser218Asp substitution) is similar to that of
R3616. When cells were treated with interferon, HSV-1(F)
still reached a titer of 2.3  108 PFU/ml. In sharp contrast,
replication of R3616 was significantly reduced to a titer of
1.4  105 PFU/ml. Under these conditions, the titers of
MC0112, MC0113, MC0115, and MC0021 are similar to
that of HSV-1(F), displaying a resistant phenotype to inter-
feron. Interestingly, the response of MC0020 and MC0114
to interferon resembled that of the 134.5 deletion mutant
R3616.
We next examined the accumulation of viral proteins
in Vero cells untreated or pretreated with interferon-
(1000 U/ml) for 20 h. At 15 h after infection, cells were
harvested, solubilized, subjected to electrophoresis on an
SDS–12% polyacrylamide gel, followed by Western blot
analysis with a polyclonal antibody against all HSV-1
antigens. Fig. 3 shows that in the presence and absence of
interferon treatment, there were similar levels of viral
protein accumulation in cells infected with wild-type
HSV-1(F), MC0112, MC0113, MC0115, and MC0021.
In cells infected with R3616, there was a dramatic re-
duction of viral protein accumulation in the presence of
interferon (lanes 5 and 6). The mutant MC0020 showed a
significant decrease in viral protein accumulation similar
to the 134.5 deletion virus R3616. Interestingly, only a
slight reduction of viral protein accumulation was de-
tected in cells infected with MC0114 in response to
interferon- treatment. From these experiments, we con-
clude that Ser209Ala, Ser209Asp, Ser218Ala, and
Trp219Tyr substitutions do not affect HSV-1 response to
interferon-. However, Arg215Leu or Ser218Asp substi-
tution in the 134.5 protein renders viral replication sen-
sitive to interferon, which correlates with decreased viral
protein accumulation for Arg215Leu substitution, but
less so for Ser218Asp substitution. The data suggest that
in addition to suppression of viral protein synthesis, in-
terferon- may inhibit other steps of the virus life cycle.
Fig. 1. (A) Schematic representation of the genome structure of HSV-1(F) and location of the 134.5 gene. The two covalently linked components of HSV-1
DNA, L and S, each consist of unique sequences, UL and Us, respectively, flanked by inverted repeats (Sheldrick and Berthelot, 1975; Wadsworth et al.,
1975). The reiterated sequences flanking UL, designated as ab and ba, are each 9 kb in size, whereas the repeats flanking Us, designated ac and ca, are
6.3 kbp in size. The location of the 134.5 gene is shown in the expanded portions of the inverted repeat sequences b and b. Since the b sequence is repeated
in an inverted orientation, there are two copies of the 134.5 gene per genome. (B) Amino acid sequence of the carboxyl-terminal domains of the wild-type
134.5 protein. The PP1-binding domain and the effector domain are outlined with thick lines. The designation of 134.5 mutants is indicated on the left.
Dashed lines indicate that no mutation is introduced. The letters in the dashed lines denote mutated amino acids, with amino acid position shown on the right.
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Protein synthesis in cells infected with wild-type or
mutant viruses
Since mutant viruses exhibited different response pat-
terns to interferon treatment, we tested the ability of these
viruses to prevent the shutoff of protein synthesis in human
neuronal SK-N-SH cells. Monolayers of SK-N-SH cells
were either mock-infected or infected with 20 PFU of wild-
type or mutant viruses per cell and incubated at 37°C. At
15 h after infection, cells were labeled for 1 h with [35S]me-
Table 1
Effect of interferon- on viral replication in Vero cellsa
Virus 134.5 gene Virus titer
IFN- IFN-
HSV-1 (F) Wild-type (3.5 2.1)  108 (2.3  1.7)  108
R3616 Deletion of 134.5 (1.1  1.6)  107 (1.4  1.0)  105
MC0112 Ser209Ala substitution (1.7 0.8)  108 (2.1  1.4)  108
MC0113 Ser209Asp substitution (2.2 0.9)  108 (1.7  1.2)  108
MC0020 Arg215Leu substitution (1.2 1.6)  107 (2.4  2.2)  105
MC0115 Ser218Ala substitution (1.7 0.8)  108 (1.5  1.3)  108
MC0114 Ser218Asp substitution (3.0 0.2)  107 (2.7  2.1)  105
MC0021 Trp219Tyr substitution (3.0 0.3)  108 (2.1  1.6)  108
a Monolayers of Vero cells were untreated or pretreated with human leukocyte interferon- (1000 U/ml) for 20 h. Cells were then infected at 0.05 PFU
per cell with the indicated viruses. At 72 h after infection, cells were harvested and virus yield was determined on Vero cells as described under Materials
and methods. Data represent the average (SD) from three independent experiments.
Fig. 2. (A) Autoradiographic images of recombinant and parental viral DNAs. Vero cells were either mock-infected or infected with the indicated viruses
at 10 PFU per cell. At 18 h after infection, cells were harvested and viral DNA was prepared as described under Materials and methods. The 134.5 gene
was then detected by hybridization to electrophoretically separated digests of viral DNA transferred to a nitrocellulose sheet with 32P-labeled NotI fragment
from the 134.5 gene. HSV-1(F) is the prototype HSV-1 strain used in this laboratory. Recombinant virus R3616 lacks 1000 bp from the coding region of
the HSV-1(F) 134.5 gene. Wild-type HSV-BAC is the parental virus DNA used to construct mutant KY0081. KY0081 is a recombinant virus that lacks 144
bp in the coding region of the 134.5 gene. HSV-1(F), HSV-BAC, MC0113, MC0020, MC0115, MC0114, and MC0021 yielded an 822-bp fragment after
digestion with NotI (lanes 1 and 4–9). KY0081 viral DNA yielded a 678-bp fragment (lane 2), and recombinant viral DNA from MC0112 yielded two bands
at 494 and 328 bp because of an introduction of an additional NotI site in the 134.5 gene (lane 3). No band was detected for R3616. (B) Expression of the
134.5 protein and its derivatives. Vero cells were either mock-infected or infected with the indicated viruses at 10 PFU per cell. At 18 h after infection, cells
were harvested, washed with phosphate-buffered saline, and resuspended in disruption buffer containing 50 mM Tris–HCl (pH 7.0), 5% 2-mercaptoethanol,
2% SDS, and 2.75% sucrose. Samples were then electrophoretically separated on a denaturing 12% polyacrylamide gel and transferred to a nitrocellulose
sheet. The blot was probed with anti-134.5 antibody. The position of the 134.5 protein and its derivatives is shown on the left.
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thionine and then harvested, solubilized in disruption buffer,
subjected to electrophoresis in a denaturing 12% polyacryl-
amide gel, and transferred to a nitrocellulose sheet and
subjected to autoradiography. The results in Fig. 4 show that
protein synthesis continued in cells either mock-infected or
infected with wild-type HSV-1(F). Similarly, in cells in-
fected with MC0112, MC0113, MC0115, and MC0021,
protein synthesis also continued. In contrast, premature
shutoff of protein synthesis was observed in cells infected
with the deletion virus R3616. Interestingly, premature
shutoff of protein synthesis was also observed in cells in-
fected with MC0020 and MC0114. These results indicate
that Arg215Leu or Ser218Asp substitution abolished the
ability of the 134.5 protein to block the shutoff of protein
synthesis in HSV-1 infected cells.
Effect of Arg215Leu or Ser218Asp substitution on the
formation of an eIF-2-specific high-molecular-weight
complex
Previous experiments showed that the 134.5 protein
binds to PP1 and forms a high-molecular-weight complex
that specifically dephosphorylates the translation initiation
factor eIF-2, thereby preventing the shutoff of protein
synthesis in cells infected with HSV-1 (He et al., 1998).
Since either Arg215 to Leu or Ser218 to Asp substitution in
the 134.5 protein abolished the ability of HSV-1 to block
the shutoff of protein synthesis in SK-N-SH cells, we
wanted to examine whether these mutants were able to form
a high-molecular-weight complex required for this function.
In this experiment, HeLa cells were infected with wild-type
HSV-1(F), MC0020, or MC0114 at 20 PFU per cell and
harvested 15 h after infection. Lysate was separated on a
Superdex 200 column, and aliquots of fractions were col-
lected. These fractions were separated on a 12% polyacryl-
amide gel, transferred to a nitrocellulose sheet, and reacted
with anti-134.5 antibody. The results in Fig. 5 show that
consistent with previous observations (He et al., 1998), the
134.5 protein eluted in two peaks (fractions 15 to 17 and 21
to 24) from lysates of cells infected with wild-type HSV-
1(F), with the first peak in fractions 15 to 17 of an unknown
nature and the second peak in fractions 21 to 24 represent-
ing a 340-kDa complex that dephosphorylates eIF-2 (He et
al., 1998). Interestingly, the 134.5 protein from lysates of
cells infected with either MC0020 or MC0114 also eluted in
two peaks, the first eluting from fractions 15 to 17 and the
second eluting from fractions 21 to 24. It is notable that the
elution profiles for these two mutants coincide well with
that of wild-type HSV-1(F). These results strongly suggest
Fig. 3. Western blot analysis of viral protein accumulation in the presence or absence of interferon. Monolayers of Vero cells were untreated or pretreated
with human leukocyte interferon- (1000 U/ml, Sigma) for 20 h. Cells were then mock-infected or infected with the indicated viruses at 0.05 PFU per cell.
At 15 h after infection, cells were harvested, washed with phosphate-buffered saline, resuspended in disruption buffer, electrophoretically separated on a
denaturing 12% polyacrylamide gel, transferred to a nitrocellulose sheet, and probed with a rabbit polyclonal antibody against all HSV-1 antigens as suggested
by the manufacturer (Dako Corporation).
Fig. 4. Autoradiographic images of [35S]methionine-labeled proteins in
SK-N-SH cells. SK-N-SH cells were mock-infected or infected with 20
PFU per cell of the indicated viruses. At 15 h after infection, the cells were
overlaid with 1 ml of medium 199 V lacking methionine but supplemented
with 50 Ci of [35S]methionine (sp act, 1000 Ci/mmol; Amersham
Pharmacia Biotech, Inc.). After 1 h of incubation in labeling medium, the
cells were harvested, solubilized in disruption buffer, subjected to electro-
phoresis on a denaturing 12% polyacrylamide gel, transferred to a nitro-
cellulose sheet, and subjected to autoradiography.
294 M. Cerveny et al. / Virology 307 (2003) 290–300
that a mutation at Arg215 to Leu or Ser218 to Asp of the
134.5 protein does not affect the formation of a high-
molecular-weight complex.
Activation of eIF-2 phosphatase activity by the 134.5
protein and its derivatives
Since a mutation in the 134.5 protein at either Arg215 to
Leu or Ser218 to Asp did not affect the formation of a
high-molecular-weight complex, we investigated the eIF-2
phosphatase activity of these mutants in HeLa cells. Ali-
quots of lysate from cells either mock-infected or infected at
20 PFU with wild-type HSV-1(F), R3616, or mutant viruses
were reacted with eIF2(32P), and samples were then pro-
cessed for autoradiography as described under Materials
and methods. As shown in Fig. 6A, lysates of cells that were
infected with MC0112, MC0113, MC0115, or MC0021
displayed eIF-2 phosphatase activity similar to that of
wild-type HSV-1(F) (Fig. 6A, lanes 3, 5, 6, 8, and 10). In
contrast, cells mock-infected or infected with the 134.5
deletion virus R3616, MC0020, or MC0114 showed no
eIF-2 phosphatase activity (Fig. 6, lanes 2, 4, 7, and 9).
These results demonstrate that Arg215Leu or Ser218Asp
substitution inhibits the 134.5 protein-mediated eIF-2 de-
phosphorylation.
To examine whether amino acid substitutions in the
effector domain of the 134.5 protein affected its binding to
PP1, we performed a GST pull-down experiment. GST–PP1
expressed from E. coli was incubated with lysates of HeLa
cells mock-infected or infected with wild-type HSV-1(F),
R3616, MC0112, MC0113, MC0114, MC0115, MC0020,
or MC0021. The protein complexes were electrophoreti-
cally separated on an SDS–12% polyacrylamide gel and
processed for immunoblot analysis with an anti-134.5 an-
tibody. The results in Fig. 6B show that GST–PP1, but not
GST, bound to the wild-type 134.5 protein. Moreover,
GST–PP1 bound to all of the mutant proteins being tested.
It is interesting that although MC0020 (Arg215Leu substi-
tution) and MC0114 (Ser218Asp substitution) failed to me-
diate eIF-2 dephosphorylation, these mutants were still
capable of binding to PP1. These observations indicate that
Arg215Leu or Ser218Asp substitution of the 134.5 protein
blocks an activity other than binding to PP1 that is required
for dephosphorylation of eIF-2.
Discussion
Evasion of antiviral response mediated by interferon is
critical for HSV-1 infection involving PKR (Harle et al.,
2002a; Khabar et al., 2000). Previous studies show that the
134.5 protein of HSV-1 is an essential viral component
required to fulfill this task (Cheng et al., 2001a; Chou and
Roizman, 1992). It appears that suppression of PKR activity
by the 134.5 protein contributes to efficient viral replica-
tion during HSV-1 infection (Cheng et al., 2001a; Chou and
Roizman, 1992; He et al., 1997; Leib et al., 2000). It has
been suggested that this activity requires the carboxyl ter-
minus of the 134.5 protein, which contains a PP1-binding
domain and an effector domain (Cheng et al., 2001b; He et
al., 1998). In this study, we further analyzed the role of the
effector domain.
Mutational analysis provided evidence that the 134.5
effector domain is involved in HSV-1 resistance to inter-
Fig. 5. Superdex 200 gel filtration analysis of 134.5 high-molecular-weight complex formation. HeLa cells were infected with wild-type HSV-1(F), MC0020
in which Arg215 is replaced with Leu, or MC0114 in which Ser218 is substituted with Asp, at 20 PFU per cell. At 15 h after infection, cells were harvested
and lysates were prepared and chromatographed as described under Materials and methods. Aliquots of fractions 15–27 from each were separated on a 12%
polyacrylamide gel, transferred to a nitrocellulose sheet, and probed with anti-134.5 antibody. The positions of the 134.5 protein and its derivatives are
indicated on the left.
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feron that is coupled to eIF-2 dephosphorylation. As
shown in Table 1, replacement of arginine 215 with leucine
(MC0020) dramatically decreased viral replication in the
presence of interferon in Vero cells, suggesting that a pos-
itively charged amino acid is essential at this position. A
similar phenotype is seen when serine 218 is substituted
with aspartic acid (MC0114), which suggests that a nega-
tively charged residue is not tolerated at this position. Con-
sistent with these observations, both mutants failed to me-
diate eIF-2 dephosphorylation, which correlated with the
shutoff of protein synthesis in SK-N-SH cells (Figs. 4 and
6A). Thus, arginine 215 and serine 218 are essential for
HSV-1 resistance to interferon. Because replacement of
serine 209 with alanine or aspartic acid had no effect on
viral replication in the absence or presence of interferon-,
these results suggest that serine 209 is not required for
HSV-1 interferon resistance. Given that the 134.5 protein
is a multifunctional protein (Bower et al., 1999; Brown et
al., 1997; Chou and Roizman, 1992; Trgovcich et al., 2002),
it is possible that serine 209 may have other virus-specific
functions in vivo. Alternatively, the conservation of serine
209 could be fortuitous. Although tryptophan 219 in the
134.5 protein is conserved, mutation of this amino acid to
tyrosine also resulted in a phenotype that is resistant to
interferon. An amino acid with an aromatic side chain at
position 219 appears sufficient to maintain the activity of
the 134.5 protein. Thus, all interferon-resistant mutants
retained their ability to prevent the translational shutoff and
to mediate eIF-2 dephosphorylation (Figs. 4 and 6A).
Collectively, these mutations define a region of the 134.5
protein involved in viral resistance to interferon.
It should be noted that in Vero cells treated with inter-
feron-, Ser218Asp substitution only slightly affected viral
protein accumulation 15 h after infection (Fig. 3, lanes 15
and 16), but significantly reduced virus yield 72 h after
infection (Table 1). While the basis for this remains un-
known, similar results have been obtained in several inde-
pendent experiments. One interpretation of these data is that
interferon- may interfere with virus activities other than
viral protein synthesis in Vero cells. One possibility is that
replication of viral DNA is inhibited by interferon-. How-
ever, this seems less likely since viral protein accumulation
was not inhibited by interferon- later in the infection (15 h)
where DNA replication has already initiated. The second
possibility is that the expression of a later gene is sup-
pressed by interferon-. Our data do not eliminate this
possibility. The third possibility is that viral maturation, for
example, capsid assembly or egress, is blocked by interfer-
on-. Additional experiments are required to test these
hypotheses.
In cells infected with HSV-1, production of double-
stranded viral RNA is thought to activate PKR, which then
phosphorylates eIF-2 (Chou et al., 1995; Chou and Roiz-
man, 1992). Upon expression of the 134.5 protein, PP1 is
recruited to form a high-molecular-weight complex, which
serves to dephosphorylate eIF-2 (He et al., 1998). Thus,
inhibition or disruption of this complex should render the
virus sensitive to interferon. It is intriguing that substitution
Fig. 6. (A) eIF-2 phosphatase activity in HeLa cells infected with recombinant HSV-1. HeLa cells were mock-infected or infected with the indicated viruses
at 20 PFU per cell. At 15 h after infection, cells were harvested and lysates were prepared as described under Materials and methods. Aliquots of lysates were
then reacted with 32P-labeled eIF-2 at 37°C. After 2 min of incubation, the reaction was stopped by adding disruption buffer. Samples were then separated
electrophoretically on a denaturing 12% polyacrylamide gel and subjected to autoradiography. The positions of the GST–PKR and eIF-2 are shown on the
left. (B) Interaction of PP1 with the 134.5 mutants. HeLa cells infected with HSV-1 expressing wild-type or mutant forms of the 134.5 protein were
harvested at 48 h after infection and lysed in buffer containing 10 mM HEPES (pH 7.6), 250 mM NaCl, 10 mM MgCl2, and 1% Triton X-100. After 30 min
on ice, the lysates were precleared with GST beads and then incubated with GST–PP1 bound to beads at 4°C overnight. After being washed three times, the
protein complexes were solubilized in disruption buffer, electrophoretically separated on a denaturing 12% polyacrylamide gel, and transferred to a
nitrocellulose sheet. The blot was probed with anti-134.5 antibody. The positions of wild-type and mutant 134.5 are shown on the left.
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of arginine 215 with leucine dramatically reduced viral
resistance to interferon-. Similarly, substitution of serine
218 with aspartic acid is deleterious. In light of these ob-
servations, it is somewhat surprising that these mutants are
still capable of forming a high-molecular-weight complex
containing the 134.5 protein and PP1, yet they are unable
to mediate eIF-2 dephosphorylation (Fig. 6A). One argu-
ment is that these mutations may affect the binding of the
134.5 protein to PP1 despite their ability to form a high-
molecular-weight complex containing 134.5. However, our
data do not support this contention. As shown in Fig. 6B,
these mutants and the wild-type 134.5 protein bound to
PP1 in a GST pull-down experiment.
The effector domain of the 134.5 protein consists of
approximately 59 amino acids (Fig. 1) which are predicted
to form three -helices joined by two turns. Recent work
suggests that the AlaArg repeats (amino acids 248 to 253) in
the third -helix of the carboxyl domain extreme are re-
quired to mediate eIF-2 dephosphorylation. Deletion of
this motif disrupted the formation of a high-molecular-
weight complex containing the 134.5 protein and PP1
(Cheng et al., 2001). This finding predicts that a mutant with
a deletion of the AlaArg motif is sensitive to interferon. Our
analysis identified a different region containing arginine 215
and serine 218, which is essential for viral resistance to
interferon, but not required for the formation of a high-
molecular-weight complex. This raises the issue of what is
the exact role of this region in the effector domain. An
intriguing possibility is that this region may participate in
the allosteric regulation of PP1. Alternatively, this region
may be involved in the interaction of the 134.5 protein with
a yet unidentified component in the complex that is required
for dephosphorylation of eIF-2. It should be pointed out
that both arginine 215 and serine 218 are located in the
region that may form a turn between the first and second
-helix. We speculate that mutations in the turn might affect
its flexibility.
The 134.5 protein is a virus-encoded PP1 regulatory
protein that contributes to HSV-1 interferon resistance (He
et al., 1997, 1998). Our results lend support to the view that
concerted action of the PP1-binding domain and the effector
domain is important for its activity. The PP1 domain of the
134.5 protein contains a signature sequence motif of (Arg/
Lys)(Val/Ile)XaaPhe, which is also present in the GM sub-
unit, a cellular PP1 regulatory protein. Structure analysis
demonstrated that the PP1-binding motif of the GM subunit
lies in the hydrophobic groove near the carboxyl terminus of
PP1 with an extended conformation (Egloff et al., 1997).
Presumably, the PP1-binding domain of the 134.5 protein
adopts a similar conformation. It is conceivable that by
binding to PP1, the 134.5 protein either targets PP1 to a
particular subcellular location or modulates the PP1 cata-
lytic activity toward eIF-2. Currently, it remains unclear
how the effector domain communicates with the PP1-bind-
ing domain in the 134.5 protein. Future structural studies
will help to resolve this issue.
Materials and methods
Cells and viruses
Vero, HeLa, and SK-N-SH cell lines were obtained from
the American Type Culture Collection and propagated in
Dulbecco’s modified Eagle’s medium supplemented with
10% (SK-N-SH) or 5% (Vero and HeLa) calf serum. HSV-
1(F) is the prototype HSV-1 strain used in this laboratory
(Ejercito et al., 1968). Recombinant virus R3616 lacks a
1000-bp fragment from the coding region of the 134.5 gene
(Chou et al., 1990). Recombinant virus KY0081 lacks a
144-bp fragment from the carboxyl-terminal region of the
134.5 gene. The following recombinant viruses each con-
tain a single amino acid substitution in the carboxyl-terminal
domain of the 134.5 gene: MC0112 (Ser209Ala), MC0113
(Ser209Asp), MC0020 (Arg215Leu), MC0115 (Ser218Ala),
MC0114 (Ser218Asp), and MC0021 (Trp219Tyr).
To construct recombinant virus KY0081, the plasmid
pKY0036 was transformed into E. coli RR1 strain that
harbored wild-type HSV-BAC by electroporation (Hors-
burgh et al., 1999). After 2 h at 30°C in LB broth, the
bacteria were plated on zeocin (Zeo)/chloramphenicol (Cm)
(25 and 20 g/ml, respectively) plates and incubated over-
night at 43°C for integration. Colonies were selected and
diluted serially in LB, plated on Cm/5% sucrose (Suc) LB
plates, and incubated at 30°C overnight. The Sucr/Cmr/Zeor
colonies were screened by polymerase chain reaction (PCR)
(94°C 5 min, then 30 cycles at 94°C, 30 s; 67°C, 30 s; 72°C,
2 min). The primers used for this purpose were OBH0018
(CCACCCCGGCACGCTCTCTGTCTC) and OBH0020
(TATATGCGCGGCTCCTGCCATCGTC), which are spe-
cific to the 134.5 gene at nucleotides 25 and 886,
respectively. In a similar way, recombinant viruses
MC0112, MC0113, MC0020, MC0115, MC0114, and
MC0021 were constructed by transformation of an RR1
strain containing KY0081 HSV-BAC DNA with pMC0112,
pMC0113, pMC0020, pMC0115, pMC0114, and pMC0021,
respectively. Positive colonies were grown in 500 ml of
LB/Cm medium, and the recombinant HSV-BAC DNA was
prepared with the aid of Qiagen plasmid purification kit.
Purified recombinant HSV-BAC DNA was then used to
transfect Vero cells using Lipofectamine reagent (Invitro-
gen). Virus was harvested 3 days after transfection. Prepa-
ration of viral stocks and titrations of infectivity were per-
formed with Vero cells.
Plasmids
Plasmid pRB143 contains the BamHI S fragment of
HSV-1(F) in the BamHI site of pRB322. To construct trans-
fer plasmids pMC0112 (Ser209Ala), pMC0113 (Ser209Asp),
pMC0020 (Arg215Leu), pMC0115 (Ser218Ala), pMC0114
(Ser218Asp), and pMC0021 (Trp219Tyr), cloning and muta-
tions in the 134.5 gene were performed by PCR using
pRB143 as the template. To construct pMC0112, a DraIII–
297M. Cerveny et al. / Virology 307 (2003) 290–300
BspEI PCR fragment was amplified with OMC0013 (GGT-
GCGCCACCTGGTGGTCTGGGCCGCGGCCGCCCGCC)
and OBH0020 and ligated into the DraIII and BspEI sites of
pMC0002, resulting in pMC0103. To construct pMC0113, a
DraIII–BspEI PCR fragment was amplified with OMC0014
(GGTGCGCCACCTGGTGGTCTGGGCCGATGCCGCCG-
CC) and OBH0020 and ligated into the DraIII and BspEI sites
of pMC0002, resulting in pMC0104. To construct pMC0020,
pMC0115, pMC0114, and pMC0021, a DraIII–BspEI PCR
fragment was amplified by two-step PCR. For construction
of pMC0020, a PCR fragment was amplified with OBH0008
(CGCCCGCCTGGCGCTCCGCGGCTCGTGGGCC) and
OBH0020, and a second PCR fragment was amplified with
OBH0018 and OBH0009 (GGCCCACGAGCCGCG-
GAGCGCCAGGCGGGCG). The resulting PCR products
were used as template, and a DraIII–BspEI PCR fragment
was amplified with OBH0018 and OBH0020 and ligated
into the DraIII and BspEI sites of pMC0002, yielding
pMC0005. For construction of pMC0115, a PCR fragment
was amplified with OMC0015 (CGCGCCGCGGCGCGT-
GGGCCCGCGA) and OBH0020, and a second PCR frag-
ment was amplified with OBH0018 and OMC0016
(TCGCGGGCCCACGCGCCGCGGCGCG). The resulting
PCR products were used as template, and a DraIII–BspEI
PCR fragment was amplified with OBH0018 and OBH0020
and ligated into the DraIII and BspEI sites of pMC0002,
yielding pMC0107. For construction of pMC0114, a PCR
fragment was amplified with OMC0017 (CGCGCCGCG-
GCGATTGGGCCCGCGA) and OBH0020, and a second
PCR fragment was amplified with OBH0018 and OMC0018
(TCGCGGGCCCAATCGCCGCGGCGCG). The resulting
PCR products were used as template, and a DraIII–BspEI
PCR fragment was amplified with OBH0018 and OBH0020
and ligated into the DraIII and BspEI sites of pMC0002,
yielding pMC0105. For construction of pMC0021, a PCR
fragment was amplified with OBH0010 (TGGCGCGCCGCG-
GCTCGTACGCCCGCGAGCGGGCC) and OBH0020, and a
second PCR fragment was amplified with OBH0018 and
OBH0011 (GGCCCGCTCGCGGGCGTACGAGCCGCG-
GCGCGCCA). The resulting PCR products were used as
template, and a DraIII–BspEI PCR fragment was amplified
with OBH0018 and OBH0020 and ligated into the DraIII
and BspEI sites of pMC0002, yielding pMC0006. To con-
struct transfer plasmid pKY0036, a BstEII–BspEI fragment
from pBH0002 was ligated into the BstEII and BspEI sites
of pRB143, yielding plasmid pKY0030. pKY0030 contains
the region of the 134.5 gene encoding amino acids 1 to
215. The BamHI S fragment of pKY0030 was then cloned
into the BamHI site of pKO5Y, yielding plasmid pKY0036.
To construct transition plasmids which encode the desired
amino acid substitution of 134.5 in the entire BamHI S
fragment of HSV-1(F), the DraIII–StuI fragment of pMC0103,
pMC0104, pMC0005, pMC0107, pMC0105, and pMC0006
was ligated into the DraIII and StuI sites of pKY0030, result-
ing in pMC0108 (Ser209Ala), pMC0109 (Ser209Asp),
pMC0015 (Arg215Leu), pMC0111 (Ser218Ala), pMC0110
(Ser218Asp), and pMC0016 (Trp219Tyr). The BamHI S frag-
ment of the transition plasmids was then cloned into the
BamHI site of pKO5Y, yielding pMC0112, pMC0113,
pMC0020, pMC0115, pMC0114, and pMC0021. To construct
pMC0002, a DraIII–BspEI fragment containing a 60-bp dele-
tion of pGF2006 was ligated into the DraIII and BspEI sites of
pMC0001. To construct pGF2006, a BstEII–BspEI PCR frag-
ment was amplified with OBH9716 (CATGGCCCGCCGC-
CGCCGCCATCGC) and OGF0013 (ATGCATCCGGATTA-
CAGGCCCGGGCACGGGCCTCGGGCCCC) and ligated
into the BstEII and BspEI sites of pGF9901 as described
previously (Cheng et al., 2001a). To construct pMC0001, the
BamHI–SphI fragment of pRB143 was ligated into the BamHI
and SphI sites of pUC19. All plasmid constructs were verified
by DNA sequence analysis.
Southern blot analysis
Vero cells were infected with viruses at 10 PFU per cell.
At 18 h after infection, cells were harvested, and viral DNA
was prepared as described previously (He et al., 1996). Viral
DNAs were verified by restriction enzyme digestion, elec-
trophoretic separation in agarose gels, transfer to nitrocel-
lulose sheets, hybridization with a 32P-labeled NotI frag-
ment of the 134.5 gene, and autoradiography as described
previously (Chou and Roizman, 1994).
Immunoblotting
Virus-infected cells were rinsed, harvested, and solubi-
lized in disruption buffer containing 50 mM Tris–HCl (pH
7.0), 5% 2-mercaptoethanol, 2% sodium dodecyl sulfate
(SDS), and 2.75% sucrose (Chou and Roizman, 1992).
Samples were then sonicated, boiled, subjected to electro-
phoresis on denaturing 12% polyacrylamide gels, trans-
ferred to nitrocellulose membranes, blocked with 5% nonfat
milk, and reacted with anti-134.5 antibody or anti-HSV-1
antigens antibody (Dako Corporation). The membranes
were rinsed in phosphate-buffered saline and reacted with
either goat anti-rabbit conjugated to alkaline phosphatase
(Bio-Rad) or donkey anti-rabbit conjugated to horseradish
peroxidase (Amersham Pharmacia Biotech, Inc.).
Plaque assay
Monolayers of Vero cells grown to 80% confluency were
either untreated or pretreated with interferon- (1000 U/ml)
for 20 h. Cells were then infected with viruses at 0.05 PFU
per cell and incubated at 37°C. At 72 h after infection, cells
were harvested and virus yields were determined on Vero
cells (Cheng et al., 2001a).
[35S]Methionine labeling of infected cells
Monolayers of SK-N-SH cells were either mock-infected
or infected with viruses at 20 PFU per cell and incubated at
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37°C. At 15 h after infection, the cells were overlaid with 1
ml of medium 199 V lacking methionine but supplemented
with 50 Ci [35S]methionine (sp act, 1000 Ci/mmol;
Amersham Pharmacia Biotech, Inc.) for 1 h. The cells were
then harvested; solubilized in disruption buffer containing
50 mM Tris–HCl (pH 7.0), 5% 2-mercaptoethanol, 2%
SDS, and 2.75% sucrose; subjected to electrophoresis in a
denaturing 12% polyacrylamide gel; transferred to a nitro-
cellulose sheet; and subjected to autoradiography (Chou and
Roizman, 1992).
Gel filtration chromatography
A Superdex 200 HR 10/30 column (1.0 by 30 cm; Am-
ersham Pharmacia Biotech, Inc.) was equilibrated with 10
mM Tris–HCl (pH 7.5), 50 mM KCl, 2 mM MgCl2, 1 mM
dithiothreitol, and 0.1 mM EDTA and pumped at 0.5 ml/
min using a fast protein liquid chromatography system
(Amersham Pharmacia Biotech, Inc.) (He et al., 1998).
Samples were injected and 0.5-ml fractions were collected
on ice, subjected to electrophoresis on a 12% polyacryl-
amide gel, transferred to a nitrocellulose membrane,
blocked with 5% nonfat milk, and reacted with anti-134.5
antibody (Cheng et al., 2002).
eIF-2 phosphatase assay
Monolayers of HeLa cells were either mock-infected or
infected with viruses at 20 PFU per cell and incubated at
37°C. At 15 h after infection, the cells were rinsed with
phosphate-buffered saline; resuspended in lysis buffer con-
taining 10 mM HEPES (pH 7.6), 150 mM NaCl, 10 mM
MgCl2, 0.2% Triton X-100, 10% glycerol, 0.5 mM phenyl-
methylsulfonyl fluoride, and 2 mM benzamidine; placed on
ice for 30 min, and subjected to centrifugation to remove
nuclei. The supernatant was then reacted with 32P-labeled
eIF-2 purified from rabbit reticulocytes as described previ-
ously (He et al., 1997). To prepare 32P-labeled eIF-2, eIF-2
was incubated with 0.17 mM [-32P]ATP (10 Ci/mmol) and
GST–PKR fusion protein in buffer containing 20 mM Tris–
HCl (pH 7.5), 40 mM KCl, 2.0 mM MgCl2 for 30 min at
37°C. GST–PKR fusion protein was expressed and purified
from E. coli BL21 cells by the addition of isopropyl--D-
thiogalactoside followed by affinity purification of the fu-
sion protein from bacterial lysates on agarose beads conju-
gated with glutathione. Aliquots of cell lysates were
incubated with phosphorylated eIF-2 in buffer containing
20 mM Tris–HCl (pH 7.5), 40 mM KCl, 2.0 mM MgCl2,
and 0.1 mM EDTA at 37°C for 2 min. The reaction was
stopped by adding disruption buffer containing 50 mM
Tris–HCl (pH 7.0), 5% 2-mercaptoethanol, 2% SDS, and
2.75% sucrose, followed by electrophoresis on a denaturing
12% polyacrylamide gel, transfer onto a nitrocellulose
membrane, and autoradiography (Cheng et al., 2001b; He et
al., 1997).
GST pull-down assay
GST protein and a GST–PP1 fusion protein were purified
from E. coli BL21 cells transformed with plasmid
pGEX4T-1 or pRB4892 as described previously (Cheng et
al., 2001). Virus-infected HeLa cells were harvested and
lysed in buffer containing 50 mM HEPES (pH 7.6), 150
mM NaCl, 10 mM MgCl2, 1% Triton X-100, 0.5 mM
phenylmethylsulfonyl fluoride, and 2 mM benzamidine. Af-
ter centrifugation to remove nuclei, the supernatant was
cleared with GST beads and then incubated with GST–PP1
fusion protein bound to beads at 4°C overnight. After wash-
ing, the proteins bound to beads were resuspended in buffer
containing 50 mM Tris–HCl (pH 7.0), 5% 2-mercaptoetha-
nol, 2% SDS, and 2.75% sucrose. Samples were subjected
to electrophoresis on an SDS–12% polyacrylamide gel and
processed for immunoblot analysis with anti-134.5 anti-
body.
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